Specific neoplastic therapy was: 15 took hormone therapy (tamoxifen and aromatase inhibitors), 9 underwent chemotherapy and/or target therapy (anthracycline and trastuzumab), 9 combined hormone therapy with chemotherapy and/or target therapy, and 9 did not undergo any adjuvant cancer therapy. This evidence concerns the gene CYP19A1 and cancer.